Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | STK16 | O75716 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448863 | 0.92 | CDK2 (0.44) | GSK3BCDK2CDK4HDAC3HDAC1 | |
| SCHEMBL3448861 | 0.91 | GSK3B (0.45) | GSK3BCDK2CDK4HDAC3HDAC1 | |
| SCHEMBL3447042 | 0.87 | KDR (0.49) | GSK3BCDK2CDK4HDAC3HDAC1 | |
| SCHEMBL3450710 | 0.84 | HDAC3 (0.49) | GSK3BCDK2CDK4HDAC3HDAC1 | |
| SCHEMBL13420261 | 0.84 | HDAC3 (0.47) | GSK3BCDK2CDK4HDAC3HDAC1 | |
| SCHEMBL3451697 | 0.84 | HDAC3 (0.47) | GSK3BCDK2CDK4HDAC3HDAC1 | |
| SCHEMBL3451039 | 0.82 | HDAC3 (0.43) | GSK3BCDK2CDK4HDAC3HDAC1 | |
| SCHEMBL3449133 | 0.81 | HDAC3 (0.44) | GSK3BCDK2CDK4HDAC3HDAC1 | |
| SCHEMBL3376420 | 0.80 | NUAK1 (0.38) | GSK3BCDK2CDK4SRCSYK | |
| SCHEMBL3450550 | 0.80 | KDR (0.42) | GSK3BCDK2CDK4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | GSK3B 2904/4885CDK2 2258/4885CDK4 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.